Posted on January 26th, 2012 by
With its $6 billion hostile offer for Illumina Inc., Swiss drug-giant Roche Holding AG is making an expensive and risky bet that genetic mapping will soon be common practice in doctors offices and hospitals…"We are convinced this is going to markedly change the way we are looking after our patients," said Gianrico Farrugia, head of the recently established Center for Individualized Medicine at the Mayo Clinic in Rochester, Minn. "But it's not a question of getting the [sequencing] data. It's a question of having mechanisms to interpret the data to make it most useful to people."
Wall Street Journal, by Jeanne Whalen and Ron Winslow, 01/25/2012
You must be logged-in to the site to post a comment.